Small-cell lung cancer (SCLC) is an aggressive malignancy that exhibits a rapid doubling
time, a high growth fraction, and the early development of widespread metastases. The …

Cytotoxic anticancer therapies activate programmed cell death in the context of underlying
stress and inflammatory signaling to elicit the emission of danger signals, cytokines, and …

This study examined the activity and safety of amrubicin monotherapy among relapsed small-
cell lung cancer (SCLC) patients who had previously been treated with atezolizumab plus …

Since the dawn of anticancer immunotherapy, the clinical use of immune checkpoint
inhibitors (ICI) has increased exponentially. Monoclonal antibodies targeting CTLA-4 and …

As a research hotspot, immune checkpoint inhibitors (ICIs) is often combined with other
therapeutics in order to exert better clinical efficacy. To date, extensive laboratory and …

Objective The aim of this meta‐analysis was to summarize the available results of
immunotherapy predictors for small cell lung cancer (SCLC) and to provide evidence‐based …

Sequential combination of immunogenic cell death (ICD)-induced interventions with
subsequent immunotherapy has shown efficacy in preclinical models and clinical …

Lung cancer (LC) is one of the most incident malignancies and a leading cause of cancer
mortality worldwide. Common tumorigenic drivers of LC mainly include genetic alterations of …

Extensive stage-Small-Cell Lung Cancer (ES-SCLC) is an aggressive cancer with dismal
prognosis. The addition of immune-checkpoint inhibitors (ICIs) to platinum-based …

Simple Summary Therapeutic efficacy of chemotherapy combined with immune checkpoint
inhibitors as first-line therapy has been previously demonstrated in extensive-stage small …